MAYPHARM launches HYALMASS AQUATOX skin solution for global market

SEOUL, South Korea, Sept. 26, 2026 /PRNewswire/ -- MAYPHARM, a global aesthetic and cosmeceutical company, is set to introduce HYALMASS AQUATOX, a new multi-active skin solution tailored for the evolving global market. This innovative formulation does not rely on a single ingredient trend but rather integrates five high-demand active elements: PDRN, Exosomes, Botulinum Peptide, GHK-Cu, and Succinic Acid, into one advanced aesthetic product.

Each component plays a unique role: Botulinum Peptide smooths the skin for a refined appearance, GHK-Cu promotes skin regeneration and conditioning, Succinic Acid revitalizes the skin with antioxidant benefits, PDRN accelerates skin regeneration, and Exosomes contribute to advanced skin rejuvenation. By merging these sought-after ingredients, HYALMASS AQUATOX aims to meet the increasing global demand for multifunctional, ingredient-focused aesthetic treatments.

This launch follows the rising international interest in MAYPHARM's HYALMASS AQUA EXOSOME, further solidifying the company's growing presence in the global aesthetic sector. As the market continues to evolve and prioritize advanced skincare solutions, MAYPHARM stresses the significance of product authenticity and proper distribution channels for HYALMASS products.

It is crucial for distributors, aesthetic professionals, and customers to verify the original manufacturer, authorized supply sources, packaging, and official product details before procuring or utilizing HYALMASS offerings. With HYALMASS AQUATOX, MAYPHARM extends its portfolio to align with emerging aesthetic trends, integrating a diverse range of high-interest actives into a single, comprehensive product concept.